Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.07 BRL | -2.83% | -3.80% | -14.73% |
May. 08 | Transcript : Raia Drogasil S.A., Q1 2024 Earnings Call, May 08, 2024 | |
May. 07 | Raia Drogasil S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 50% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- With an expected P/E ratio at 31.89 and 23.56 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.73% | 8.5B | B | ||
+30.76% | 1.29B | - | ||
-9.96% | 345M | - | ||
+11.11% | 229M | - | - | |
-10.09% | 86.22M | - | - | |
-43.65% | 82.6M | C | ||
+24.09% | 62.2M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RADL3 Stock
- Ratings Raia Drogasil S.A.